How Orforglipron Affects ALT

Why ALT usually falls: weight loss clears fat from the liver, and fatty liver is the most common reason for a mildly raised ALT. As liver fat falls, ALT tends to fall with it, the same pattern seen with semaglutide and tirzepatide.

Why the class was watched: small-molecule GLP-1 agonists are processed by the liver, unlike the peptide drugs. Pfizer's lotiglipron was stopped after transaminase rises in about 6% of participants, and danuglipron was dropped in April 2025 after a possible drug-induced liver injury. Orforglipron is a different chemical structure and has not shown the same signal.

Orforglipron is metabolised mainly by CYP3A4. Exposure rises 1.7-fold in moderate and 4.6-fold in severe liver impairment, and it is not recommended in severe impairment.

Pooled phase 3 data (7 trials, 11,220 people, up to 104 weeks): mean ALT and AST decreased on orforglipron. ALT or AST above 3x the upper limit with bilirubin above 2x happened in 6 people (0.1%) on orforglipron and 6 (0.1%) on comparators, all with alternative explanations. No Hy's Law cases attributed to the drug (Wharton 2026, PMID 42338042).

Caveat: the weight-management trials excluded people starting with ALT or AST at 3x the upper limit or more, which is a common baseline in people running oral steroids.

Label: no liver-monitoring requirement and no hepatotoxicity warning.

Baseline: ALT, AST, GGT and bilirubin before starting. If you train hard or use oral steroids, add GGT and CK so you can tell muscle-driven AST and ALT from liver.

Follow-up: recheck at week 4 to 6 and at 3 months, and after any new oral compound.

Interpretation: a falling ALT is the expected direction. A rising ALT after starting orforglipron is worth working up rather than assuming it is the drug, especially if oral AAS, alcohol or new supplements started in the same window.

• ALT under 3x the upper limit and falling or stable: no action beyond routine follow-up.
• ALT above 3x the upper limit, or any rise with raised bilirubin, dark urine or jaundice: stop orforglipron and see a doctor the same week.
• On oral steroids: stop the oral first if ALT climbs; it is the far more likely cause. See TUDCA and NAC doses for liver protection.
• Grey-market orforglipron has unknown purity, and liver toxicity is exactly where a poorly made small molecule would show up.

Full monitoring panel and Australian status: When will orforglipron be available in Australia?